In adults with overweight or obesity and CVD, but without diabetes, semaglutide reduced MACE at a mean 40 mo.
Where this comes from
- Record sourced from PubMed, PMID 38437690.
- Also identified by DOI 10.7326/J24-0008.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al; SELECT Trial Investigators. <b>Semaglutide and cardiovascular outcomes in obesity without diabetes.</b> N Engl J Med. 2023;389:2221-2232. 37952131.
Medical subject headings
- Cardiovascular Diseases
- Diabetes Mellitus, Type 2
- Glucagon-Like Peptides